SBS-226

SBS-226 is a first-in-class small molecule drug that acts as a dual mu opioid receptor (MOR) partial agonist and delta opioid receptor (DOR) full antagonist. It is being developed for the treatment of opioid use disorder (OUD) and opiate withdrawal syndrome (OWS). Structurally, SBS-226 is a synthetic derivative of mitragynine pseudoindoxyl, one of the primary alkaloids found in kratom. Preclinical studies indicate that SBS-226 can ameliorate opioid withdrawal symptoms without demonstrating abuse potential, respiratory depression, or physical dependence. Unlike current medications for OUD, it does not precipitate withdrawal in animals chronically exposed to potent opioids. The compound was synthesized and developed in the Majumdar Lab and is currently under development by Sparian Biosciences[2][4][6][8].